|
시장보고서
상품코드
1655486
유방암 치료제 시장Breast Cancer Therapeutics |
||||||
Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
세계 유방암 치료제 시장은 2030년까지 904억 달러에 이를 전망
2024년에 451억 달러로 추정된 유방암 치료제 세계 시장은 2024-2030년의 분석 기간에 CAGR 12.3%로 성장하여 2030년에는 904억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 표적치료는 CAGR 12.6%를 나타내고, 분석 기간 종료까지 749억 달러에 이를 것으로 예측됩니다. 화학요법 부문의 성장률은 분석 기간 CAGR 11.0%로 추정됩니다.
미국 시장은 115억 달러로 추정, 중국은 CAGR 16.2%로 성장 예측
미국의 유방암 치료제 시장은 2024년에 115억 달러에 이른 것으로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 219억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년간 CAGR은 16.2%를 나타낼 전망입니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 8.1%와 10.0%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 9.1%로 성장할 것으로 예측됩니다.
세계의 유방암 치료제 시장 동향과 촉진요인
현대 유방암 치료제 구성요소와 치료에 대한 영향이란?
유방암 치료제는 유방암 세포를 표적으로 삼아 제거하기 위해 고안된 다양한 치료법을 포함합니다. 이러한 치료법에는 호르몬 요법, 화학 요법, 분자 표적 치료, 그리고 최근에는 면역 요법이 포함됩니다. 호르몬 요법은 체내에서 호르몬을 생산하는 능력을 억제하거나 유방암 세포에 대한 호르몬의 작용을 억제하여 호르몬 수용체 양성 유방암을 표적으로 삼습니다. 화학요법은 종양을 축소하기 위한 수술 전(신보조요법) 또는 수술 후 잔존하는 암세포를 파괴하기 위한 수술 후(보조요법)에 사용되며, 여전히 기본적인 치료법입니다. 표적치료제와 면역치료제는 유방암의 증식과 전이와 관련된 분자 경로를 특이적으로 표적으로 삼는 새로운 약제군입니다. 이러한 치료법의 발전으로 유방암 환자의 생존율과 삶의 질이 크게 향상되었으며, 개인 맞춤형 치료는 종양학에서 달성 가능한 목표가 되었습니다.
기술의 발전은 유방암 치료에 어떤 영향을 미치고 있는가?
기술의 발전은 유방암 치료의 상황을 극적으로 변화시키고 있습니다. 예를 들어, 유전체 검사 기술의 발달로 개별 암의 특성을 보다 정확하게 파악할 수 있게 되어 각 환자에게 가장 효과적인 치료법을 선택할 수 있게 되었습니다. 정밀의학(Precision Medicine)으로 알려진 이 접근법은 개별 유전자 프로파일에 맞게 치료를 조정하여 부작용을 최소화하면서 치료 효과를 높입니다. 또한, 영상 진단 및 수술 기술의 발전으로 주변 건강한 조직을 최대한 보존하면서 종양을 발견하고 완전히 제거할 수 있게 되었습니다. 진단 과정에서의 인공지능의 통합 또한 유방암 진단의 정확성과 속도를 높여 조기에 발견할 수 있도록 돕고 있습니다.
유방암 치료제의 새로운 트렌드는?
유방암 치료제의 새로운 트렌드는 보다 최소침습적이고 표적화된 치료법으로의 전환을 포함합니다. 호르몬 요법에 반응하지 않는 아형인 삼중음성 유방암을 치료하기 위한 PARP 억제제 개발에 대한 관심이 높아지고 있습니다. 호르몬 수용체 양성 유방암에서 CDK4/6 억제제를 사용하는 것도 진행성 암 환자에게 새로운 희망을 가져다주는 추세입니다. 또한, 생존기간 연장뿐만 아니라 치료와 관련된 부작용을 줄여 삶의 질을 향상시킬 수 있는 치료법 개발에도 점점 더 많은 관심이 쏠리고 있습니다. 또한, 두 가지 이상의 약물을 사용하여 암세포를 서로 다른 방식으로 공격하는 병용요법 동향도 단독요법에 대한 내성을 극복할 수 있는 새로운 방법을 제공하는 것으로 주목받고 있습니다.
유방암 치료제 시장의 성장을 가속하는 요인은 무엇일까?
유방암 치료제 시장의 성장은 전 세계 유방암 유병률 증가, 효과적인 치료에 대한 수요 증가 등 여러 요인에 의해 이루어집니다. 또한, 새로운 신약 타겟과 치료 요법의 발견으로 이어지는 암 연구의 발전도 시장 확대에 크게 기여하고 있습니다. 또한, 인식 개선과 검진 프로그램으로 조기 진단이 가능해지면서 조기 치료 및 완치 가능성이 있는 치료 대상 환자 수가 증가하고 있습니다. 의료 보험 적용 범위의 확대와 전 세계 의료비 지출 증가는 이러한 치료법에 대한 접근성을 높여 시장 성장을 뒷받침하고 있습니다. 또한, 임상시험 중인 유방암 치료제의 강력한 파이프라인은 치료 옵션의 지속적인 개선과 확장을 약속하며, 이 분야에 대한 지속적인 투자와 관심을 보장하고 있습니다. 이러한 역학은 의료 수요와 기술 혁신이 모두 시장을 주도하고 있다는 점을 강조하며 종양학 분야에서 시장의 중요성을 강조합니다.
부문
치료(표적치료, 화학요법, 호르몬요법, 면역요법)
조사 대상 기업 예(주요 26개사)
- AstraZeneca PLC
- Celgene Corporation
- Eisai Co., Ltd.
- Eli Lilly and Company
- Novartis International AG
- Pfizer, Inc.
- Roche Diagnostics
- Sanofi
- Teva Pharmaceutical Industries Ltd.
목차
제1장 조사 방법
제2장 주요 요약
- 시장 개요
- 주요 기업
- 시장 동향과 촉진요인
- 세계 시장 전망
제3장 시장 분석
- 미국
- 캐나다
- 일본
- 중국
- 유럽
- 프랑스
- 독일
- 이탈리아
- 영국
- 스페인
- 러시아
- 기타 유럽
- 아시아태평양
- 호주
- 인도
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 아르헨티나
- 브라질
- 멕시코
- 기타 라틴아메리카
- 중동
- 이란
- 이스라엘
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동
- 아프리카
제4장 경쟁
LSH 25.03.13
Global Breast Cancer Therapeutics Market to Reach US$90.4 Billion by 2030
The global market for Breast Cancer Therapeutics estimated at US$45.1 Billion in the year 2024, is expected to reach US$90.4 Billion by 2030, growing at a CAGR of 12.3% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$74.9 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 11.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$11.5 Billion While China is Forecast to Grow at 16.2% CAGR
The Breast Cancer Therapeutics market in the U.S. is estimated at US$11.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$21.9 Billion by the year 2030 trailing a CAGR of 16.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.1% and 10.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR.
Global Breast Cancer Therapeutics Market - Key Trends & Drivers Summarized
What Constitutes Modern Breast Cancer Therapeutics and Their Impact on Treatment?
Breast cancer therapeutics encompass a wide range of medical treatments designed to target and eliminate breast cancer cells. These treatments include hormonal therapies, chemotherapy, targeted therapy, and increasingly, immunotherapy. Hormonal therapies target hormone-receptor-positive breast cancers by blocking the body’s ability to produce hormones or by interfering with the effects of hormones on breast cancer cells. Chemotherapy remains a cornerstone treatment, used either before surgery (neoadjuvant therapy) to shrink tumors or after (adjuvant therapy) to destroy any remaining cancerous cells. Targeted therapies and immunotherapies represent a newer class of drugs that specifically target molecular pathways associated with breast cancer growth and spread. The evolution of these treatments has significantly improved survival rates and quality of life for breast cancer patients, making personalized medicine an achievable goal in oncology.
How Are Technological Advancements Influencing Breast Cancer Treatment?
Technological advancements are drastically reshaping the landscape of breast cancer treatment. The development of genomic testing technologies, for example, allows for more precise identification of individual cancer characteristics, guiding the selection of therapies that are most likely to be effective for each patient. This approach, known as precision medicine, tailors treatment to individual genetic profiles, enhancing treatment efficacy while minimizing side effects. Furthermore, advancements in imaging and surgical techniques have improved the detection and complete removal of tumors while preserving as much of the surrounding healthy tissue as possible. The integration of artificial intelligence in diagnostic processes also promises to enhance the accuracy and speed of breast cancer diagnostics, supporting early and reliable detection.
What Are the Emerging Trends in Breast Cancer Therapeutics?
Emerging trends in breast cancer therapeutics include a shift towards less invasive and more targeted treatment options. There is growing interest in the development of PARP inhibitors for treating triple-negative breast cancer, a subtype that does not respond to hormonal therapies. The use of CDK4/6 inhibitors in hormone receptor-positive breast cancer is another trend, offering new hope for patients with advanced cancer. Additionally, there is an increasing focus on developing therapies that provide not only longer survival but also better quality of life by reducing treatment-related side effects. The trend towards combination therapies, which use two or more drugs to attack cancer cells in different ways, is also gaining traction, offering new ways to overcome resistance to single-drug treatments.
What Drives the Growth of the Breast Cancer Therapeutics Market?
The growth in the breast cancer therapeutics market is driven by several factors, including the rising prevalence of breast cancer globally, which increases the demand for effective treatments. Advances in cancer research that lead to the discovery of novel drug targets and treatment regimens also contribute significantly to the expansion of the market. Furthermore, growing awareness and screening programs have led to earlier diagnosis, increasing the number of patients eligible for early-stage and potentially curative therapies. The expansion of healthcare coverage and increased healthcare spending globally enable greater access to these treatments, supporting market growth. Moreover, the strong pipeline of breast cancer drugs in clinical trials promises continuous improvement and expansion of treatment options, ensuring ongoing investment and interest in the sector. These dynamics underscore a market driven by both medical need and innovation, highlighting its critical importance in the field of oncology.
SCOPE OF STUDY:
The report analyzes the Breast Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Therapy (Targeted Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 26 Featured) -
- AstraZeneca PLC
- Celgene Corporation
- Eisai Co., Ltd.
- Eli Lilly and Company
- Novartis International AG
- Pfizer, Inc.
- Roche Diagnostics
- Sanofi
- Teva Pharmaceutical Industries Ltd.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Breast Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Advances in Oncology Research Propel Growth in Breast Cancer Therapeutics Market
- Increasing Incidence of Breast Cancer Expands Addressable Market Opportunity
- Technological Innovations in Targeted Therapies Generate Demand for Advanced Treatments
- Growth in Personalized Medicine Drives Adoption of Breast Cancer Therapeutics
- Rising Awareness and Early Detection Strengthens Business Case for Therapeutic Solutions
- Adoption of Immunotherapies Spurs Growth in Breast Cancer Treatment
- Impact of Genetic Testing and Biomarkers Expands the Market for Personalized Therapies
- Demand for Minimally Invasive Treatments Generates Opportunities for Innovation
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Breast Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Breast Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 17: USA Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 18: USA Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: USA 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- CANADA
- TABLE 20: Canada Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: Canada Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: Canada 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- JAPAN
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 23: Japan Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 24: Japan Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: Japan 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- CHINA
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 26: China Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: China Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: China 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- EUROPE
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 29: Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Breast Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: Europe 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 32: Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: Europe Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: Europe 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- FRANCE
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 35: France Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: France Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: France 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- GERMANY
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 38: Germany Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Germany Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: Germany 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- ITALY
- TABLE 41: Italy Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Italy Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: Italy 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 44: UK Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: UK Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: UK 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- SPAIN
- TABLE 47: Spain Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Spain Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: Spain 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- RUSSIA
- TABLE 50: Russia Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Russia Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Russia 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Rest of Europe Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Rest of Europe 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 57: Asia-Pacific Historic Review for Breast Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Asia-Pacific 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Asia-Pacific Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Asia-Pacific 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- AUSTRALIA
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 62: Australia Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: Australia Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: Australia 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- INDIA
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 65: India Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: India Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: India 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- SOUTH KOREA
- TABLE 68: South Korea Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: South Korea Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: South Korea 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Rest of Asia-Pacific Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Rest of Asia-Pacific 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- LATIN AMERICA
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 74: Latin America Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 75: Latin America Historic Review for Breast Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: Latin America 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 77: Latin America Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Latin America Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Latin America 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 80: Argentina Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Argentina Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Argentina 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- BRAZIL
- TABLE 83: Brazil Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Brazil Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Brazil 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- MEXICO
- TABLE 86: Mexico Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Mexico Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Mexico 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Rest of Latin America Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Rest of Latin America 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- MIDDLE EAST
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 92: Middle East Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 93: Middle East Historic Review for Breast Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Middle East 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 95: Middle East Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Middle East Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Middle East 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- IRAN
- TABLE 98: Iran Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Iran Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Iran 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- ISRAEL
- TABLE 101: Israel Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Israel Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Israel 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- SAUDI ARABIA
- TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Saudi Arabia Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Saudi Arabia 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 107: UAE Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: UAE Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: UAE 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Rest of Middle East Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Rest of Middle East 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- AFRICA
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 113: Africa Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Africa Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: Africa 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
IV. COMPETITION
Global Breast Cancer Therapeutics Market to Reach US$90.4 Billion by 2030
The global market for Breast Cancer Therapeutics estimated at US$45.1 Billion in the year 2024, is expected to reach US$90.4 Billion by 2030, growing at a CAGR of 12.3% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$74.9 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 11.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$11.5 Billion While China is Forecast to Grow at 16.2% CAGR
The Breast Cancer Therapeutics market in the U.S. is estimated at US$11.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$21.9 Billion by the year 2030 trailing a CAGR of 16.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.1% and 10.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR.
Global Breast Cancer Therapeutics Market - Key Trends & Drivers Summarized
What Constitutes Modern Breast Cancer Therapeutics and Their Impact on Treatment?
Breast cancer therapeutics encompass a wide range of medical treatments designed to target and eliminate breast cancer cells. These treatments include hormonal therapies, chemotherapy, targeted therapy, and increasingly, immunotherapy. Hormonal therapies target hormone-receptor-positive breast cancers by blocking the body’s ability to produce hormones or by interfering with the effects of hormones on breast cancer cells. Chemotherapy remains a cornerstone treatment, used either before surgery (neoadjuvant therapy) to shrink tumors or after (adjuvant therapy) to destroy any remaining cancerous cells. Targeted therapies and immunotherapies represent a newer class of drugs that specifically target molecular pathways associated with breast cancer growth and spread. The evolution of these treatments has significantly improved survival rates and quality of life for breast cancer patients, making personalized medicine an achievable goal in oncology.
How Are Technological Advancements Influencing Breast Cancer Treatment?
Technological advancements are drastically reshaping the landscape of breast cancer treatment. The development of genomic testing technologies, for example, allows for more precise identification of individual cancer characteristics, guiding the selection of therapies that are most likely to be effective for each patient. This approach, known as precision medicine, tailors treatment to individual genetic profiles, enhancing treatment efficacy while minimizing side effects. Furthermore, advancements in imaging and surgical techniques have improved the detection and complete removal of tumors while preserving as much of the surrounding healthy tissue as possible. The integration of artificial intelligence in diagnostic processes also promises to enhance the accuracy and speed of breast cancer diagnostics, supporting early and reliable detection.
What Are the Emerging Trends in Breast Cancer Therapeutics?
Emerging trends in breast cancer therapeutics include a shift towards less invasive and more targeted treatment options. There is growing interest in the development of PARP inhibitors for treating triple-negative breast cancer, a subtype that does not respond to hormonal therapies. The use of CDK4/6 inhibitors in hormone receptor-positive breast cancer is another trend, offering new hope for patients with advanced cancer. Additionally, there is an increasing focus on developing therapies that provide not only longer survival but also better quality of life by reducing treatment-related side effects. The trend towards combination therapies, which use two or more drugs to attack cancer cells in different ways, is also gaining traction, offering new ways to overcome resistance to single-drug treatments.
What Drives the Growth of the Breast Cancer Therapeutics Market?
The growth in the breast cancer therapeutics market is driven by several factors, including the rising prevalence of breast cancer globally, which increases the demand for effective treatments. Advances in cancer research that lead to the discovery of novel drug targets and treatment regimens also contribute significantly to the expansion of the market. Furthermore, growing awareness and screening programs have led to earlier diagnosis, increasing the number of patients eligible for early-stage and potentially curative therapies. The expansion of healthcare coverage and increased healthcare spending globally enable greater access to these treatments, supporting market growth. Moreover, the strong pipeline of breast cancer drugs in clinical trials promises continuous improvement and expansion of treatment options, ensuring ongoing investment and interest in the sector. These dynamics underscore a market driven by both medical need and innovation, highlighting its critical importance in the field of oncology.
SCOPE OF STUDY:
The report analyzes the Breast Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Therapy (Targeted Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 26 Featured) -
- AstraZeneca PLC
- Celgene Corporation
- Eisai Co., Ltd.
- Eli Lilly and Company
- Novartis International AG
- Pfizer, Inc.
- Roche Diagnostics
- Sanofi
- Teva Pharmaceutical Industries Ltd.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Breast Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Advances in Oncology Research Propel Growth in Breast Cancer Therapeutics Market
- Increasing Incidence of Breast Cancer Expands Addressable Market Opportunity
- Technological Innovations in Targeted Therapies Generate Demand for Advanced Treatments
- Growth in Personalized Medicine Drives Adoption of Breast Cancer Therapeutics
- Rising Awareness and Early Detection Strengthens Business Case for Therapeutic Solutions
- Adoption of Immunotherapies Spurs Growth in Breast Cancer Treatment
- Impact of Genetic Testing and Biomarkers Expands the Market for Personalized Therapies
- Demand for Minimally Invasive Treatments Generates Opportunities for Innovation
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Breast Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Breast Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 17: USA Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 18: USA Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: USA 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- CANADA
- TABLE 20: Canada Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: Canada Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: Canada 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- JAPAN
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 23: Japan Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 24: Japan Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: Japan 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- CHINA
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 26: China Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: China Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: China 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- EUROPE
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 29: Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Breast Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: Europe 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 32: Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: Europe Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: Europe 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- FRANCE
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 35: France Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: France Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: France 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- GERMANY
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 38: Germany Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Germany Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: Germany 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- ITALY
- TABLE 41: Italy Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Italy Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: Italy 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 44: UK Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: UK Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: UK 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- SPAIN
- TABLE 47: Spain Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Spain Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: Spain 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- RUSSIA
- TABLE 50: Russia Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Russia Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Russia 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Rest of Europe Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Rest of Europe 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 57: Asia-Pacific Historic Review for Breast Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Asia-Pacific 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Asia-Pacific Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Asia-Pacific 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- AUSTRALIA
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 62: Australia Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: Australia Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: Australia 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- INDIA
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 65: India Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: India Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: India 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- SOUTH KOREA
- TABLE 68: South Korea Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: South Korea Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: South Korea 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Rest of Asia-Pacific Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Rest of Asia-Pacific 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- LATIN AMERICA
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 74: Latin America Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 75: Latin America Historic Review for Breast Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: Latin America 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 77: Latin America Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Latin America Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Latin America 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 80: Argentina Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Argentina Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Argentina 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- BRAZIL
- TABLE 83: Brazil Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Brazil Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Brazil 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- MEXICO
- TABLE 86: Mexico Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Mexico Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Mexico 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Rest of Latin America Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Rest of Latin America 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- MIDDLE EAST
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 92: Middle East Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 93: Middle East Historic Review for Breast Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Middle East 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 95: Middle East Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Middle East Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Middle East 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- IRAN
- TABLE 98: Iran Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Iran Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Iran 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- ISRAEL
- TABLE 101: Israel Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Israel Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Israel 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- SAUDI ARABIA
- TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Saudi Arabia Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Saudi Arabia 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 107: UAE Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: UAE Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: UAE 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Rest of Middle East Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Rest of Middle East 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
- AFRICA
- Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 113: Africa Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Africa Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: Africa 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
